Mithila Samachar

Developmental and Epileptic Encephalopathies Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Developmental and Epileptic Encephalopathies Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

November 14
22:45 2022
Developmental and Epileptic Encephalopathies Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
DelveInsight Business Research LLP
DelveInsight’s “Developmental and Epileptic Encephalopathy – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the DEE, historical and forecasted epidemiology as well as the DEE market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Developmental and Epileptic Encephalopathy – Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the DEE, historical and forecasted epidemiology as well as the DEE market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The DEE market report provides current treatment practices, emerging drugs, DEE market share of individual therapies, and current and forecasted DEE market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current DEE treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Developmental and Epileptic Encephalopathies  Market Report:

  • In the coming years, DEE market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market

  • The companies and academics are working to assess challenges and seek opportunities that could influence DEE R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     

  • Major players are involved in developing therapies for DEE. Launch of emerging therapies will significantly impact the DEE market

  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for DEE

  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Key benefits of the report:

  • The report covers the descriptive overview of DEE, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

  • Comprehensive insight has been provided into the DEE epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for DEE are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of DEE market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global DEE market

Got queries? Click here to learn more about Developmental and Epileptic Encephalopathies  Market Insights 

 

Developmental and Epileptic Encephalopathies Overview

Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. The syndromes of epileptic encephalopathies with onset in the neonatal period, infancy, and early childhood include early myoclonic encephalopathy, Ohtahara syndrome, West syndrome, Dravet syndrome (severe myoclonic epilepsy in infancy), Lennox–Gastaut syndrome (LGS), Landau–Kleffner syndrome (LKS), Epilepsy with continuous spike-and-waves during slow-wave sleep, Doose Syndrome (myoclonic atonic epilepsy), CDKL5 deficiency disorder (CDD), Tuberous sclerosis complex (TSC), SCN8A-DEE, and KCNQ2-DEE.

The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states. Moreover, Brain computed tomography (CT) scanning, and more specifically, magnetic resonance imaging (MRI) is also indicated. These should be performed before steroid treatment, which may lead to apparent atrophy on the CT or MRI scan.

The approach to the treatment of epileptic encephalopathy has some of the general principles and approaches to pediatric epilepsy treatment. The most appropriate anti-epileptic treatment is selected based on the type of epilepsy syndrome. Antiseizure medications include clobazam, vigabatrin, zonisamide, phenobarbital, benzodiazepines, vigabatrin, and others used for the treatment of DEE. Steroid therapies, vagus nerve stimulation, a ketogenic diet and epilepsy surgery are also used for the management of DEE.

Developmental and Epileptic Encephalopathies Epidemiological Insights:

 

  • The total diagnosed prevalent cases of DEE in the 7MM were 253,157 in 2021, growing at a CAGR of 0.73% during the study period (2019–2032).

  • Epidemiology assessed for the condition showed that the US, in 2021, accounted for approximately 129,437 diagnosed prevalent cases of DEE.

  • Among the EU-5 countries in 2021, Germany had the highest diagnosed prevalent population of DEE with 21,041 cases, followed by France (17,258) and UK (16,381). In contrast, Spain had the lowest cases (11,743) in 2021.

  • Japan accounted for 23,798 diagnosed prevalent DEE cases in 2021.

  • LGS accounted for the highest number of diagnosed prevalent cases in 7MM. 79,396 cases, were observed in 2021 which are expected to increase by 2032.

  • In EU5 countries, the diagnosed prevalent cases of Tuberous sclerosis complex were highest in Germany with 4,651 in 2021.

Developmental and Epileptic Encephalopathies Epidemiological Segmentation 

 

  • Total  Developmental and Epileptic Encephalopathies  diagnosed cases

  • Total  Developmental and Epileptic Encephalopathies treated  Diagnosed Prevalent cases   

Developmental and Epileptic Encephalopathies Market Outlook

Currently, the commonly used treatment therapy is antiepileptic medications. The early treatment choice for almost all patients with multiple seizures is AEDs. The medications treat the symptoms of epilepsy (seizures) and are highly effective and completely control seizures in the majority (70%) of cases. The drugs prevent seizures from starting by reducing brain cells’ tendency to send excessive and confused electrical signals. The choice of medication depends on a variety of factors, some of which include the type of seizure and type of epilepsy, the likely side effects of the medication, other medical conditions the patient may have, potential interactions with the patient’s other medications, age, gender and cost of the medication. Anticonvulsant therapy is also considered after two unprovoked epileptic seizures. The medication prescribed by the medical practitioner could be monotherapy or a combinational therapy, including two or more products as a medication.

 

Learn more by requesting for sample @ Developmental and Epileptic Encephalopathies Market Landscape

Developmental and Epileptic Encephalopathies Key Companies

  • Jazz Pharmaceuticals

  • Biocodex

  • Zogenix (Acquired by UCB)

  • Lundbeck

  • Marinus Pharmaceuticals

  • Novartis

  • Aquestive Therapeutics

  • And many others 

 

Table of Contents

  1. Key Insights 

  2. Report Introduction 

  3. Executive Summary of Developmental and Epileptic Encephalopathies  

  4. Disease Background and Overview

  5. Epidemiology and patient population 

  6. Developmental and Epileptic Encephalopathies Emerging Therapies

  7. Developmental and Epileptic Encephalopathies Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Appendix

  10.  Developmental and Epileptic Encephalopathies Report Methodology

  11.  DelveInsight Capabilities

  12.  Disclaimer

  13. About DelveInsight

Click here to read more about Developmental and Epileptic Encephalopathies Market Insights

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/